Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Drug Test Anal ; 11(7): 1009-1017, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30784204

RESUMEN

Pharmaceutical research not only provides the basis for the development of new medicinal products but also for the synthesis of new drugs of abuse. 3-Fluorophenmetrazine (3-FPM), a fluorinated derivative of the anorectic phenmetrazine, was first patented in 2011 and appeared on the drug market in 2014. Though invented for potential medical purposes, pharmacokinetic data on this compound, crucial for interpreting forensic as well as clinical cases, are not available. Therefore, a liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) method for the detection of 3-FPM in serum, urine, and oral fluid was developed, validated for urine and serum, and used to quantify 3-FPM in samples obtained during a controlled self-experiment. The method proved to be linear, selective and sufficiently sensitive. The limits of detection (LODs) were 0.1 ng/mL, 0.2 ng/mL, and 0.05 ng/mL in serum, urine, and oral fluid. Inter-day precision and intra-day precision (RSD) in serum samples were below 6.3% and below 8.5%, respectively. The highest serum concentration (cmax ) of 210 ng/mL was reached 2.5 hours (tmax ) after ingestion. The elimination half-life and the volume of distribution were calculated to be approx. 8.8 hours and 400 L (5.3 L/kg). 3-FPM could be detected in serum and urine up to 82 hours and 116 hours, respectively. It was still detected in the last oral fluid sample taken 55 hours after ingestion. 3-FPM was mainly excreted unchanged. Main metabolic reactions were aryl-hydroxylation and N-hydroxylation. Interestingly, the product of oxidative ring opening (2-amino-1-(3-fluorophenyl)propan-1-ol) showed the largest window of detection in the self-experiment.


Asunto(s)
Estimulantes del Sistema Nervioso Central/farmacocinética , Drogas de Diseño/farmacocinética , Fenmetrazina/análogos & derivados , Estimulantes del Sistema Nervioso Central/sangre , Estimulantes del Sistema Nervioso Central/orina , Cromatografía Liquida/métodos , Humanos , Límite de Detección , Masculino , Persona de Mediana Edad , Fenmetrazina/sangre , Fenmetrazina/farmacocinética , Fenmetrazina/orina , Saliva/metabolismo , Espectrometría de Masa por Ionización de Electrospray/métodos , Detección de Abuso de Sustancias/métodos , Espectrometría de Masas en Tándem/métodos
2.
AAPS J ; 21(4): 70, 2019 05 31.
Artículo en Inglés | MEDLINE | ID: mdl-31152318

RESUMEN

Phenmetrazine, a selective dopamine and norepinephrine releaser, previously available as an oral anorectic, is prone to be abused. This study aimed to assess the feasibility of delivering phenmetrazine via the transdermal route for a new indication, while also minimizing its abuse potential. The passive permeation of phenmetrazine through dermatomed human cadaver skin was evaluated using static Franz diffusion cells at 10 mg/mL for the fumarate salt, and at 20, 40, and 80 mg/mL for the free base in propylene glycol for 24 h. Further, oleic acid (5% w/w), oleyl alcohol (5% and 10% w/w), and lauric acid (10% w/w) were investigated as chemical permeation enhancers to enhance the delivery. Skin irritation potential was assessed using EpiDerm™ in vitro reconstructed human epidermal model. The free base showed superior 24-h delivery (8.13 ± 4.07%, 10.6 ± 2.5%, and 10.4 ± 1.4% for groups with 20, 40, and 80 mg/mL of the free base, respectively) to phenmetrazine fumarate salt (undetectable). The successful screening of effective chemical enhancers, oleyl alcohol (5% and 10% w/w), oleic acid (5% w/w), and lauric acid (10% w/w) resulted in significant enhancement of delivery. The calculated therapeutic relevant flux for the potential indication, attention deficit hyperactivity disorder, 20 µg/cm2/h was met, where a 24-mg daily dose from a 50-cm2 patch was projected to be delivered to a 60-kg individual. Irritation study results suggest that formulations with therapeutically relevant delivery are likely to be non-irritant. In conclusion, it is feasible to deliver therapeutically relevant amounts of phenmetrazine via the transdermal route.


Asunto(s)
Depresores del Apetito/farmacocinética , Dermatitis Irritante/etiología , Fenmetrazina/farmacocinética , Piel/metabolismo , Administración Cutánea , Depresores del Apetito/administración & dosificación , Depresores del Apetito/toxicidad , Dermatitis Irritante/metabolismo , Composición de Medicamentos , Reposicionamiento de Medicamentos , Estudios de Factibilidad , Humanos , Técnicas In Vitro , Fenmetrazina/administración & dosificación , Fenmetrazina/toxicidad , Piel/efectos de los fármacos , Absorción Cutánea , Pruebas de Irritación de la Piel
3.
Forensic Sci Int ; 303: 109959, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31546164

RESUMEN

The organ distribution of 3-fluorophenmetrazine (3-FPM), pyrazolam, diclazepam as well as its main metabolites delorazepam, lormetazepam and lorazepam, was investigated. A solid phase extraction (SPE) and a QuEChERS (acronym for quick, easy, cheap, effective, rugged and safe) - approach were used for the extraction of the analytes from human tissues, body fluids and stomach contents. The detection was performed on a liquid chromatography-tandem mass spectrometry system (LCMS/MS). The analytes of interest were detected in all body fluids and tissues. Results showed femoral blood concentrations of 10 µg/L for 3-FPM, 28 µg/L for pyrazolam, 1 µg/L for diclazepam, 100 µg/L for delorazepam, 6 µg/L for lormetazepam, and 22 µg/L for lorazepam. Tissues (muscle, kidney and liver) and bile exhibited higher concentrations of the mentioned analytes than in blood. Additional positive findings in femoral blood were for 2-fluoroamphetamine (2-FA, approx. 89 µg/L), 2-flourometamphetamine (2-FMA, hint), methiopropamine (approx. 2.2 µg/L), amphetamine (approx. 21 µg/L) and caffeine (positive). Delorazepam showed the highest ratio of heart (C) and femoral blood (P) concentration (C/P ratio = 2.5), supported by the concentrations detected in psoas muscle (430 µg/kg) and stomach content (approx. 210 µg/L, absolute 84 µg). The C/P ratio indicates that delorazepam displays susceptibility for post-mortem redistribution (PMR), supported by the findings in muscle tissue. 3-FPM, pyrazolam, diclazepam, lorazepam and lormetazepam did apparently not exhibit any PMR. The cause of death, in conjunction with autopsy findings was concluded as a positional asphyxia promoted by poly-drug intoxication by arising from designer benzodiazepines and the presence of synthetic stimulants.


Asunto(s)
Benzodiazepinas/farmacocinética , Drogas de Diseño/farmacocinética , Diazepam/análogos & derivados , Fenmetrazina/análogos & derivados , Cambios Post Mortem , Adulto , Benzodiazepinas/análisis , Bilis/química , Líquidos Corporales/química , Química Encefálica , Drogas de Diseño/análisis , Diazepam/análisis , Diazepam/farmacocinética , Toxicología Forense , Contenido Digestivo/química , Humanos , Riñón/química , Hígado/química , Lorazepam/análogos & derivados , Lorazepam/análisis , Lorazepam/farmacocinética , Pulmón/química , Masculino , Nordazepam/análogos & derivados , Nordazepam/análisis , Nordazepam/farmacocinética , Líquido Pericárdico/química , Fenmetrazina/análisis , Fenmetrazina/farmacocinética , Músculos Psoas/química , Espectrometría de Masas en Tándem
4.
J Pharm Biomed Anal ; 128: 485-495, 2016 Sep 05.
Artículo en Inglés | MEDLINE | ID: mdl-27372653

RESUMEN

Wastewater-based epidemiology (WBE) as means to estimate illicit drug and new psychoactive substance (NPS) consumption with spatial and temporal resolution is gaining increasing attention. In order to evaluate a given NPS using WBE, in vivo metabolism and microbial biotransformation of excretion products and unchanged compounds need evaluation. The aims of this study were to identify in vivo phase I and II metabolites of the NPS 3-fluorophenmetrazine (3-FPM) in human and rat urine and study the in vitro contribution of Cytochrome P450 (CYP) isoenzymes in phase I metabolism. Additionally, to study microbial biotransformation products (MBPs) of 3-FPM from incubations in wastewater and in a wastewater isolated Pseudomonas Putida strain. To these aims gas chromatography and liquid chromatography coupled to mass spectrometry were applied. Metabolites and MBPs were isolated from urine and microbial incubations after solid phase extraction and precipitation with or without enzymatic conjungate cleaving. The main transformation pathways were N-oxidation, aryl hydroxylation and subsequent O-methylation, alkyl hydroxylation, oxidation, and degradation of the ethyl-bridge yielding the O/N-bis-dealkylated metabolite, combinations thereof and further glucuronidation or sulfations. The main excretion products in the human urine sample were the unchanged compound and the N-oxide, and the main MBPs were the N-oxide and hydroxylation with subsequent oxidations on the alpha-methyl position. Based on these findings, the proposed strategy for WBE analysis of 3-FPM is quantitative determination of unchanged 3-FPM together with qualitative verification of a number of selected metabolites to verify consumption and rule out discharge.


Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Inactivación Metabólica , Fenmetrazina/análogos & derivados , Pseudomonas putida/metabolismo , Animales , Cromatografía Liquida , Cromatografía de Gases y Espectrometría de Masas , Humanos , Isoenzimas/metabolismo , Masculino , Fenmetrazina/farmacocinética , Fenmetrazina/orina , Ratas , Extracción en Fase Sólida , Aguas Residuales/microbiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA